NPI 1528446499: Open Payments
NPI 1528446499. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$317 in 17 payments from 7 companies in 2025. Trend: 2023 $0 · 2024 $107 · 2025 $317
Food & beverage: $317
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 4 | $83 |
| Novo Nordisk Inc | 4 | $75 |
| Exact Sciences Corporation | 3 | $53 |
| Boston Scientific Corporation | 3 | $43 |
| MILLICENT US INC | 1 | $23 |
| Astellas Pharma US Inc | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
Products named: KISUNLA, The Cologuard Plus Collection Kit, Infinion 16, Wegovy, Ozempic, INTRAROSA, Veozah, NUZYRA.
